

MEETING ABSTRACT

Open Access

# Biosynthetic pathway deflection – a new cell line engineering approach


Hans Henning von Horsten, Thomas Rose, Volker Sandig\*

From 22nd European Society for Animal Cell Technology (ESACT) Meeting on Cell Based Technologies Vienna, Austria. 15-18 May 2011

With increasing information on genome, transcriptome and metabolome of commonly used production cell lines, engineering becomes an increasingly popular approach to achieve desired product attributes, growth behavior and nutrient consumption. Tools range from feeding intermediate metabolites, overexpression or deregulation of key enzymes of a pathway to knock-out and RNA silencing. While conceptually simple, the latter approaches are either labor intensive or costly to apply at large scale.

## Fucose targeted glycoengineering

Aiming at glycan modulation we added another principle to this toolbox: enzymatic deflection of a biochemical pathway. Fucose is synthesized inside the cell from GDP-mannose via short lived intermediates before it is transported to the Golgi apparatus for attachment to the nascent glycan (Figure 1). A bacterial enzyme is used to redirect synthesis towards a heterologous activated hexose that cannot be utilized by the cell resulting in depletion of the natural pathway (deflecting enzyme,



**Figure 1** Overview of GDP-L-Fucose Biosynthesis showing the point of substrate deflection within the fucose de-novo synthesis pathway.

**Table 1 CDC42-mediated relative mAb-titer increase over native clone titers. The clones represent five different products.**

Titers of Naïve mAb producing clones [g/l]	Titers of cdc42-engineered mAb producing clones [g/l]	Relative Fold Increase per modified clone
0,8	1,65	<b>2,06</b>
0,9	2,2	<b>2,4</b>
2,3	3,0	<b>1,3</b>
2,6	4,5	<b>1,73</b>
0,8	1,65	<b>2,06</b>

Figure 1). To our surprise, even lowest level expression of the enzyme completely abolishes fucose synthesis in stably modified cells.

The approach allows producing antibodies that are devoid of core fucose at Fc glycans of the CH2 domain [1]. This modification provides higher flexibility to the Fc-region of IgG1 antibodies and enhances their binding to the Fc $\gamma$ RIIIa receptor of NK cells - the dominating effector cells in antibody dependent cytotoxicity (ADCC). Consequently, the potency of antibodies directed against tumor or infected cells is substantially increased.

In contrast to other strategies the approach is easily applied to the starter cell line of choice and, moreover, allows modification of fully developed producer cell lines within weeks.

### Simultaneous regulation of multiple cellular pathways

Another concept for clone engineering is based on simultaneous modulation of multiple cellular processes. We found that the Rho GTPase *cdc42* is a highly suitable effector molecule for this purpose. This pleiotropic modulator dramatically boosts antibody titers when overexpressed in the cytosol of pharmaceutical producer clones (Table1).

Published: 22 November 2011

#### Reference

1. von Horsten HH, Ogorek C, Blanchard V, Demmler C, Giese C, Winkler K, Kaup M, Berger M, Jordan I, Sandig V: **Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase.** *Glycobiology* 2010, **20**(12):1607-18.

doi:10.1186/1753-6561-5-S8-O4

**Cite this article as:** von Horsten *et al.*: Biosynthetic pathway deflection – a new cell line engineering approach. *BMC Proceedings* 2011 **5**(Suppl 8):O4.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit

